Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification

Oncogene volume 30, pages 4097–4106 (2011)Cite this article

Subjects

Abstract

Lapatinib, a dual tyrosine kinase inhibitor of the epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), is clinically active in patients with breast cancer positive for HER2 amplification. The mechanism of this anti-tumor action has remained unclear, however. We have now investigated the effects of lapatinib in HER2 amplification-positive breast cancer cells with or without an activating PIK3CA mutation. Lapatinib induced apoptosis in association with upregulation of the pro-apoptotic protein Bcl-2 interacting mediator of cell death (BIM) through inhibition of the MEK-ERK signaling pathway in breast cancer cells with HER2 amplification. RNA interference (RNAi)-mediated depletion of BIM inhibited lapatinib-induced apoptosis, implicating BIM induction in this process. The pro-apoptotic effect of lapatinib was less pronounced in cells with a PIK3CA mutation than in those without one. Lapatinib failed to inhibit AKT phosphorylation in PIK3CA mutant cells, likely because of hyperactivation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway by the mutation. Depletion of PIK3CA (a catalytic subunit of PI3K) revealed that survivin expression is regulated by the PI3K pathway in these cells, suggesting that insufficient inhibition of PI3K-survivin signaling is responsible for the limited pro-apoptotic effect of lapatinib in HER2 amplification-positive cells with a PIK3CA mutation. Consistent with this notion, depletion of survivin by RNAi or treatment with a PI3K inhibitor markedly increased the level of apoptosis in PIK3CA mutant cells treated with lapatinib. Our results thus suggest that inhibition of both PI3K-survivin and MEK-ERK-BIM pathways is required for effective induction of apoptosis in breast cancer cells with HER2 amplification.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Altieri DC . (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46–54.

    Article  CAS  Google Scholar 

  • Ambrosini G, Adida C, Altieri DC . (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917–921.

    Article  CAS  Google Scholar 

  • Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395–402.

    CAS  Google Scholar 

  • Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H et al. (2009). Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 106: 22299–22304.

    Article  CAS  Google Scholar 

  • Burris III HA, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N et al. (2009). A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 15: 6702–6708.

    Article  CAS  Google Scholar 

  • Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393–403.

    Article  CAS  Google Scholar 

  • Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ et al. (2007). BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4: 1669–1679; discussion 1680.

    Article  CAS  Google Scholar 

  • Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL . (2008). Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118: 3651–3659.

    Article  CAS  Google Scholar 

  • Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A . (2007). Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4: 1681–1689; discussion 1690.

    Article  CAS  Google Scholar 

  • Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC et al. (2008). Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544–5552.

    Article  CAS  Google Scholar 

  • Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W et al. (2008). Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68: 9221–9230.

    Article  CAS  Google Scholar 

  • Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743.

    Article  CAS  Google Scholar 

  • Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S et al. (2008). Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999–3005.

    Article  CAS  Google Scholar 

  • Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X et al. (2007). Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4: e294.

    Article  Google Scholar 

  • Gymnopoulos M, Elsliger MA, Vogt PK . (2007). Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104: 5569–5574.

    Article  CAS  Google Scholar 

  • Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K et al. (2009). in vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15: 4649–4664.

    Article  CAS  Google Scholar 

  • Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992–11000.

    Article  CAS  Google Scholar 

  • Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW . (2001). Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93: 1541–1552.

    Article  CAS  Google Scholar 

  • Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H . (2010). Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21: 255–262.

    Article  CAS  Google Scholar 

  • Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630–1639.

    Article  CAS  Google Scholar 

  • LoRusso PM, Jones SF, Koch KM, Arya N, Fleming RA, Loftiss J et al. (2008). Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 26: 3051–3056.

    Article  CAS  Google Scholar 

  • McKenzie JA, Liu T, Goodson AG, Grossman D. . (2010). Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 inte. Cancer Res 70: 7927–7937.

    Article  CAS  Google Scholar 

  • Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA et al. (2000). A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805–2809.

    CAS  Google Scholar 

  • Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden DL . (2010). The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol (e-pub ahead of print 24 October 2010; DOI:10.1007/s00280-1010-1486-7).

  • Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554–2559.

    Article  CAS  Google Scholar 

  • Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.

    Article  CAS  Google Scholar 

  • Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022–8030.

    Article  CAS  Google Scholar 

  • Slamon DJ . (1990). Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest 8: 253.

    Article  CAS  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.

    Article  CAS  Google Scholar 

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.

    Article  CAS  Google Scholar 

  • Speliotes EK, Uren A, Vaux D, Horvitz HR . (2000). The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol Cell 6: 211–223.

    Article  CAS  Google Scholar 

  • Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M et al. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084–6091.

    Article  CAS  Google Scholar 

  • Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N . (2000). Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127–134.

    CAS  PubMed  Google Scholar 

  • Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y et al. (2009). Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101: 1676–1682.

    Article  CAS  Google Scholar 

  • Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL et al. (2000). Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 10: 1319–1328.

    Article  CAS  Google Scholar 

  • Zhang H, Liu G, Dziubinski M, Yang Z, Ethier SP, Wu G . (2008). Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat 112: 217–227.

    Article  CAS  Google Scholar 

  • Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM . (2005). The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102: 18443–18448.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank E Hatashita, K Kuwata, and H Yamaguchi for technical assistance.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, Japan

    J Tanizaki, I Okamoto, S Fumita, W Okamoto & K Nakagawa

  2. Department of Genome Biology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, Japan

    K Nishio

Authors
  1. J Tanizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Fumita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Nishio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Okamoto.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tanizaki, J., Okamoto, I., Fumita, S. et al. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene 30, 4097–4106 (2011). https://doi.org/10.1038/onc.2011.111

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2011.111

Keywords

This article is cited by

Search

Advanced search

Quick links